Get the Stockscreener App
9.86
1.20%
-0.12
After Hours:
9.86
CorMedix Inc Stock (CRMD) Latest News
CorMedix supports CMS policy updates - TipRanks
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - The Manila Times
CorMedix: Major CMS Policy Change to Boost DefenCath Access for 30% of Dialysis Patients | CRMD Stock News - StockTitan
CorMedix Approves Key Governance and Incentive Changes - TipRanks
Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com India
When the Price of (CRMD) Talks, People Listen - Stock Traders Daily
Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Best Momentum Stocks To Buy For November 8th - Barchart
Best Momentum Stocks to Buy for November 8th - Yahoo Finance
Trend Tracker for (CRMD) - Stock Traders Daily
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com Australia
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com India
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High? - Yahoo Finance
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium - The Manila Times
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts - Simply Wall St
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic - Yahoo Finance UK
CorMedix: Q3 Earnings Snapshot - AOL
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Recent 23% pullback isn't enough to hurt long-term CorMedix (NASDAQ:CRMD) shareholders, they're still up 188% over 1 year - Simply Wall St
CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call Transcript - Insider Monkey
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - MSN
CorMedix Inc. Reports Q3 2024 Financial Results - TipRanks
CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth By Investing.com - Investing.com South Africa
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth - Investing.com India
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update - The Manila Times
CorMedix earnings beat by $0.06, revenue topped estimates - Investing.com UK
Stellantis N.V. (STLA-N) QuotePress Release - The Globe and Mail
Cormedix Inc (CRMD) Q3 2024 Earnings Report Preview: What To Loo - GuruFocus.com
CorMedix stock soars to 52-week high, hits $13.52 - Investing.com India
CorMedix 2.0: New Leadership, New Approval, New Focus (NASDAQ:CRMD) - Seeking Alpha
CorMedix stock soars to 52-week high, hits $13.52 By Investing.com - Investing.com UK
(CRMD) Trading Advice - Stock Traders Daily
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Spotify Technology S.A. (SPOT-N) QuotePress Release - The Globe and Mail
CorMedix Inc. Announces New Data at ASN Kidney Week 2024 - The Manila Times
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade - MSN
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):